TRU Signs Five Year Manufacturing Agreement for SUS Supply

NZX/ASX Announcement
1 September 2022

TruScreen Signs Five Year Manufacturing Agreement
for critical Supply of SUS
Key Highlights
• TruScreen has signed a five-year manufacturing agreement with Zapco International Limited for
the critical supply of Single Use Sensors (SUS)
• The agreement confirms TruScreen’s confidence in growing demand for TruScreen cervical
cancer screening medical device.
• Agreement will facilitate closer cooperation between the parties to affect product design and
manufacturing optimisation and efficiencies to reduce the cost of SUS and improve TruScreen’s
market competitiveness.
TruScreen Group Limited (NZX/ASX: TRU) (‘TruScreen’ or ‘the Company’) is pleased to announce that it has
executed a five-year manufacturing contract with its current critical supplier, Zapco International Limited, for
the manufacture and supply of Single Use Sensors.
Zapco has been manufacturing for TruScreen since the launch of the TruScreen cervical cancer screening
device. The new contract signals a closer working relationship of the two companies to collaborate on initiatives
to affect design and cost improvements for the benefit of our patients, distributors and the market generally.
TruScreen has identified a number of initiatives that will improve manufacturing yield and process optimisations
which when completed will result in a meaningful reduction in the SUS cost.
The contract provides for Zapco to implement identified cost improvement initiatives and to pass these benefits
to the Company. The Company continues to own all Intellectual Property associated with the product and any
developments, modifications and enhancements or improvements.
The contract contains other conditions which are standard for a supply contract of this nature.
TruScreen CEO Juliet Hull said: “the SUS usage is a key consumable component impacting on the financial
performance of TruScreen. With SUS demand growing, year on year from greater placement of our screening
devices in the market and expected to be well over 200,000 units this year, any improvements in manufacturing
yield and process can make a material contribution to our bottom line.
We look forward to continue working with our strategic supplier, Zapco to optimise our processes for the benefit
of both parties.”
This announcement has been approved by the Board.
-ENDS-
For more information, visit

www.truscreen.com or contact:
Juliet Hull
Chief Executive Officer
juliethull@truscreen.com

Guy Robertson
Chief Financial Officer
guyrobertson@truscreen.com

Julia Maguire
Investor Relations
julia@thecapitalnetwork.com.au

+61 2 8999 3699

About TruScreen:

TruScreen Group Limited (NZX/ASX: TRU) is a New Zealand-based medical device company that
has developed an AI-enabled device that can detect precancerous and cancerous cervical changes
in real-time via optical and electrical measurements of cervical tissue. Unlike many cervical screening
technologies that have only triage/adjunct functionality, the TruScreen device is registered as a
primary screening tool.
TruScreen’s cervical screening technology effectively resolves many of the ongoing issues with
conventional cytology, including failed samples, poor patient follow-up, patient discomfort, and the
need for supporting laboratory infrastructure.
The device is CE-marked, meaning it meets EU safety, health and environmental protection standards
required for sale and use throughout Europe. It is also National Medical Products Administration
approved for sale in China. In 2021, TruScreen established a manufacturing facility in China for
devices marketed and sold in China.
TruScreen is currently targeting product sales to a range of low and middle-income countries,
including China, Mexico, Vietnam, Russia, Zimbabwe and Saudi Arabia, where no large-scale cervical
cancer screening programmes and infrastructure are currently in place. By doing so, the Company
hopes to help improve the health and wellbeing of women worldwide.
To learn more, please visit: www.truscreen.com/